News from amo pharma limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 13, 2019, 07:30 ET Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited...


May 06, 2019, 10:09 ET AMO Pharma Presents Statistical Analysis of Results of Phase 2 Study of AMO-02 in Adolescents with Autism Spectrum Disorder

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited...


Apr 16, 2019, 08:30 ET AMO Pharma Announces Launch of First Clinician-Completed Rating Scale for Congenital Myotonic Dystrophy Type 1

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited...


Oct 29, 2018, 11:16 ET AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited...


Oct 23, 2018, 10:17 ET AMO Therapeutics Announces Presentation of Concordant Analysis of Results of Phase 2 Study of AMO-02 in treatment of myotonic dystrophy

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating diseases with limited or no treatment...


Jun 13, 2018, 09:45 ET AMO Pharma Receives FDA Orphan Drug Designation for AMO-04 in Treatment of Rett Syndrome

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating diseases with limited or no treatment...


May 07, 2018, 11:26 ET AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders...


Mar 15, 2018, 12:41 ET AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders...


Oct 18, 2017, 03:00 ET AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders...


Sep 25, 2017, 03:00 ET AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders...


Jul 27, 2017, 03:00 ET AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


Jul 20, 2017, 03:00 ET AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


May 30, 2017, 03:00 ET AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


Mar 14, 2017, 04:00 ET AMO Pharma Enters into Collaboration Agreement with Ranedis Pharmaceuticals for Development of RND-001

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


Feb 28, 2017, 02:00 ET AMO Pharma Joins with Leaders in Patient and Caregiver Advocacy to Commemorate Rare Disease Day

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases including rare genetic diseases with...


Jun 07, 2016, 08:00 ET AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


Apr 18, 2016, 03:00 ET Joseph Horrigan Joins AMO Pharma as Chief Medical Officer

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...


Sep 30, 2015, 03:00 ET AMO Pharma Ltd. Closes $25 Million Private Equity Financing with Woodford Patient Capital Trust plc

AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, ...